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Abstract
Human prostate tumor vaccine and gene therapy trials using ex vivo methods to prime dendritic cells (DCs) with prostate
specific membrane antigen (PSMA) have been somewhat successful, but to date the lengthy ex vivo manipulation of DCs
has limited the widespread clinical utility of this approach. Our goal was to improve upon cancer vaccination with tumor
antigens by delivering PSMA via a CD40-targeted adenovirus vector directly to DCs as an efficient means for activation and
antigen presentation to T-cells. To test this approach, we developed a mouse model of prostate cancer by generating clonal
derivatives of the mouse RM-1 prostate cancer cell line expressing human PSMA (RM-1-PSMA cells). To maximize antigen
presentation in target cells, both MHC class I and TAP protein expression was induced in RM-1 cells by transduction with an
Ad vector expressing interferon-gamma (Ad5-IFNc). Administering DCs infected ex vivo with CD40-targeted Ad5-huPSMA, as
well as direct intraperitoneal injection of the vector, resulted in high levels of tumor-specific CTL responses against RM-1-
PSMA cells pretreated with Ad5-IFNc as target cells. CD40 targeting significantly improved the therapeutic antitumor
efficacy of Ad5-huPSMA encoding PSMA when combined with Ad5-IFNc in the RM-1-PSMA model. These results suggest that
a CD-targeted adenovirus delivering PSMA may be effective clinically for prostate cancer immunotherapy.
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Introduction
Prostate cancer ranks second among the leading cancer-related
deaths in the United States in men, and an estimated 240,890 new
cases and 33,720 deaths will have occurred in 2011 [1]. Although
treatments are available for organ-confined carcinoma of prostate,
there is no effective approach to treat recurrent disease after
androgen deprivation therapy fails. This calls for the development
of novel strategies to combat this disease. Recent reports suggest
suppression of prostate tumor growth is possible following
immunization strategies using vaccines encoding tumor antigens
[2,3]. Prostate specific membrane antigen (PSMA) is a type II
membrane protein with folate hydrolase activity expressed
primarily in prostate epithelium and a limited number of other
cell types. This well-defined prostate expression is significantly
elevated in prostate cancer, especially in advanced stages [4].
Thus, PSMA is a favorable potential target for prostate cancer
immunotherapy. Several PSMA-based vaccines had been de-
veloped and clinical trials indicate that these immunotherapy
approaches can be safely administered and can induce immune
responses in patients with advanced carcinoma of prostate [5,6].
However, limited clinical responses observed so far warrant an
alternative vaccination paradigm.
Dendritic cells (DCs) are the professional APCs that play
a potent role in the initiation of immune response by activating T-
cells. It is known that interaction of DCs through CD40 with T
helper cells expressing the CD40 ligand (CD40L) can aid in their
maturation that in turn triggers CTL response. Previous reports
have shown that ex vivo DC-based vaccines can induce specific
anti-tumor T-cell responses in patients [7,8,9]. Despite these
clinical successes, this approach is limited from widespread clinical
application because manipulating DCs through ex vivo culture and
antigen loading is laborious, expensive, and time consuming.
Likewise, ex vivo prepared DCs show limited migration to the
lymph nodes for subsequent activation of T-cells [10]. This
problem has been addressed by in situ loading of DCs with tumor
associated antigens using viral and non-viral vectors [11]. Among
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the viral vectors, recombinant adenoviral vectors (Ads) have
received much attention for cancer therapy because of their high
capacity and robust gene expression [12]. Nonetheless, Ad vectors
poorly infect DCs because of a lack in expression of the Coxsackie
and adenovirus receptor mediating infectious uptake [13]. This
limitation could be overcome by using a bispecific adapter
molecule that encompasses a fusion of an extracellular domain
of the native Coxsackie and adenovirus receptor receptor and the
mouse CD40 ligand linked by a trimerization motif from the T4
bacteriophage fibritin protein [14,15]. More recently, this adapter
was used successfully for DC-based immunotherapy in a mouse
model of melanoma [16,17]. However, other tumor/antigen
combinations have not been tested.
In the present study, we evaluated a dendritic cell-targeted Ad
vaccine expressing human PSMA in vivo in a mouse model of
prostate cancer. We generated an immunocompetent model using
the RM-1 mouse prostate cancer cell line that form tumors in
syngeneic C57BL6 mice [18], by constitutively expressing the
human PSMA antigen. Herein, we show that in vivo delivery of
a CD40-targeted Ad5 vector leads to increased cytotoxic T cell
responsiveness and enhanced therapeutic efficacy in this model.
We also demonstrate that IFNc as an immunological adjuvant in
our vaccine regime increased antigen presentation in target cells
and maximized this effect.
Materials and Methods
Ethics Statement
All animals used in this study received humane care based on
guidelines set by the American Veterinary Association as well as in
accordance with the Guide for the Care and Use of Laboratory Animals
(Institute for Laboratory Animal Research, Washington, DC). The
experimental protocols involving live animals were reviewed and
approved by the Institutional Animal Care and Use Committee of
LSU Health Sciences Center at Shreveport (protocol P-10-040).
All efforts were made to minimize animal suffering, to reduce the
number of animals used and to utilize alternatives to in vivo
techniques, if available.
Cell Lines
RM-1, an androgen-insensitive MHC class I–deficient mouse
prostate cancer cell line, which is syngeneic in C57BL/6 mice
[18], was obtained from Dr. Timothy C. Thompson (Baylor
College of Medicine, Scott Department of Urology, Houston,
TX). The human transformed embryonic kidney HEK-293 cell
line was obtained from the American Type Culture Collection
(ATCC; Manassas, VA). The cells were maintained at 37uC and
a 5% humidified CO2 atmosphere in Dulbecco’s Minimum
Essential Medium (DMEM, Mediatech Inc.; Manassas, VA),
containing 10% fetal bovine serum (FBS, Gemini Bioproducts;
Woodland, CA) and 1% antibiotic-antimycotic solution (Media-
tech Inc.; Manassas, VA).
Animals
Male C57BL/6 mice at 4–6 weeks of age were obtained from
Charles River Laboratories (Wilmington, MA).
Generating RM-1 Tumor Cells Expressing Recombinant
Human PSMA and GFP
Human elongation factor 1a-subunit promoter (EF-1a) was
chosen as a transgene promoter. The human PSMA and the GFP
coding sequences were cloned into pEF1/Myc-His vector (In-
vitrogen; Carlsbad, CA). Constructs with the correct restriction
pattern were selected and sequenced, and were used for trans-
fection of RM-1 cells. Cells were then selected by 0.8 mg/mL
Figure 1. Growth characteristics of transfected cell lines in vitro.
Shown is a representative growth curve of the number of RM-1 cells
(N) in culture with time compared with the number of RM-1-PSMA
clone 1 cells (.), RM-1-PSMA clone 3 cells (X), and RM-1-GFP clone 2
cells (&). Each data point represents the mean 6 standard error of
three independent experiments.
doi:10.1371/journal.pone.0046981.g001
Figure 2. Western blot analysis of PSMA protein levels in RM-1
mouse prostate cancer cell lines. Protein extracts (20 mg) were
prepared from each cell line and diluted with RIPA sample buffer. The
extracts were separated by SDS-PAGE, electroblotted onto nitrocellu-
lose and probed with an anti-human PSMA antibody directed to the C-
terminal protein sequence (A) or an anti-human PSMA antibody
directed to the N-terminal protein sequence (B), followed by treatment
with corresponding anti-species IgG HRP conjugates. Shown are
representative blots after visualization by autoradiography.
doi:10.1371/journal.pone.0046981.g002
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G418 (Alexis) for 2 weeks to obtain single clone. Expression of
recombinant human PSMA expression in antibiotic resistant
clones was determined by Western blot analysis (using the method
described below) with an anti-PSMA monoclonal antibodies
recognizing the N-terminus (7E11C5; previously purified from
a hybridoma obtained at ATCC) or the C-terminus (YPSMA-1,
Abcam; Cambridge, MA). Two clones expressed detectable level
of PSMA (RM-1-PSMA clone 1 and RM-1-PSMA clone 3). They
were propagated and frozen for further analysis. The RM-1 clones
expressing GFP were identified by fluorescence microscopy. One
positive clone (RM-1-GFP clone 2) was expanded and frozen for
further analysis.
Adenoviral Vectors
Ad5-huPSMA was constructed by subcloning the human PSMA
cDNA coding sequence into the MfeI - BstXI sites of the
pAdenoVatorCMV5 shuttle vector (QBiogene; Carlsbad, CA).
The resulting pAdenoVatorCMV5-hu-PSMA shuttle vector was
used to construct an adenovirus by homologous recombination
with pAdEasy1 (containing the E1 and E3 deleted Ad5 backbone)
in E. coli using methods previously described [19]. The resultant
recombinant plasmid was linearized with Pac I and transfected
into HEK-293 cells to generate the Ad5-huPSMA virus. The Ad5-
luc1, a human Ad serotype 5 vector containing a firefly luciferase
expression cassette within the E1 deleted region was provided by
Dr Igor Dmitriev (Washington University School of Medicine, St.
Louis, MO). The Ad5-IFNc, a human Ad serotype 5 vector,
consisting of an E1-deleted human serotype 5 Ad with a chicken b-
actin promoter driving the expression of the mouse IFNc cDNA
was provided by Dr. Hirofumi Hamada (Department of Molecular
Medicine, Sapporo Medical University, Sapporo, Japan). The
adenovirus stocks were propagated and amplified using the human
transformed embryonic kidney HEK-293 cell line. High titer
adenovirus stocks were purified using an Adenopure purification
kit (Puresyn, Inc, Malvern, PA). Following purification the viruses
were quantified using an Adeno-X Rapid Titer Kit (BD
Biosciences, Palo Alto, CA). The viruses were dialyzed overnight
in dialysis buffer (potassium phosphate buffered saline containing
1 M sucrose and 0.5% b-cyclodextrin) at 4uC before storage at
280uC.
CD40 Targeting Ligand
A recombinant molecular adaptor protein consisting of the
soluble extracellular domain of the Coxsackie and adenovirus
receptor linked to the mouse CD40 ligand via a trimerzation motif
(CFm40L) was constructed, produced and purified as described
previously [14], and used to retarget adenoviral vectors to mouse
DC.
Western Blot Analysis of TAP Expression
Control RM-1 cells and RM-1 cells incubated for 24 h with
Ad5-IFNc at multiplicity of infection (MOI) of 100 ifu/cell were
harvested and lysates were prepared in RIPA sample buffer.
Protein concentrations of the samples were normalized by
Bradford assay. Samples were run on 10% sodium dodecyl
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) gels and
transferred to nitrocellulose membranes. Membranes were
blocked for 1 h with 5% bovine serum albumin (BSA) and washed
Figure 3. Western blot analysis of PSMA protein levels in adenovirus-infected dendritic cells. (A) Protein extracts (20 mg) were prepared
from cultured mouse dendritic cells after infection for 24 h with the CD40-targeted Ad5-luc1 or CD40-targeted Ad5-mPSMA expressing mouse PSMA
or Ad5-huPSMA expressing human PSMA. (B) Protein extracts (20 mg) were prepared from cultured mouse dendritic cells after infection for 0, 24, or
48 h with the CD40- Ad5-huPSMA expressing human PSMA. Each cell extract was prepared using RIPA sample buffer. The extracts were separated by
SDS-PAGE, electroblotted onto nitrocellulose membranes and probed with an anti-human PSMA antibody followed by treatment with the
corresponding anti-mouse IgG HRP conjugates. Shown are representative blots after visualization by autoradiography. A loading control was used by
co-treatment of the membranes with an anti-mouse a-tubulin antibody.
doi:10.1371/journal.pone.0046981.g003
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with TTBS (1% Tween-20 in Tris-buffered saline). Afterwards, the
membranes were incubated with anti-mouse TAP1, anti-mouse
TAP2, or anti-mouse GAPDH antibodies (Santa Cruz Bio-
technology; Santa Cruz, CA) for 1 h. After three consecutive
washes with TTBS, membranes were incubated with horseradish
peroxidase-conjugated goat anti-mouse IgG antibody for 1 h, and
washed three times for 30 min each with TTBS. Finally the
membranes were developed using the ECL substrate (Amersham;
Piscataway, NJ), and exposed to X-ray film.
Flow Cytometry Analysis of MHC Class I Expression
RM-1 cells (parental as well as RM-1-PSMA clones expressing
human PSMA) were analyzed for the cell surface expression of
MHC class I (Db and Kb). Briefly, RM-1 cells were infected for
24 h with Ad5-IFNc at MOI 100. At 24 h post-incubation, cells
were harvested and immunostained by using a fluorescein
isothiocyanate (FITC) labeled anti-mouse H-2Kb/H-2Db anti-
body (BD Biosciences; San Jose, CA). This antibody reacts with
the mouse H-2Kb MHC class I alloantigen haplotype and cross-
reacts with H-2Db, but does not react with other haplotypes. Cells
were incubated with the antibody (1:1000 dilution) for 20 min at
Figure 4. Flow cytometry analysis of MHC class I cell surface expression in RM-1 cells maintained in the absence and presence of
IFNc. Evaluation of binding of anti-MHC class I (H-2Db and H-2Kb) antibodies to (A) RM-1 parental cells, (B) RM-1-GFP clone 2 cells, (C) RM-1-PSMA
clone 1 cells, and (D) RM-1-PSMA clone 3 cells. Shown are histogram peaks corresponding to untreated (shaded) and cells infected with Ad5-IFNc
(unshaded).
doi:10.1371/journal.pone.0046981.g004
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4uC and washed 3 times in ice-cold PBS. An isotype antibody
(mouse IgG2a, k) was also used to immunostain cells as a negative
control. Subsequently, the cells were fixed in 1% paraformalde-
hyde for 5 min in the dark, washed twice with ice-cold PBS and
resuspended in 200 uL of PBS buffer to be analyzed by flow
cytometry (FACSCalibur; BD Biosciences).
Preparing Bone Marrow-derived DCs
Bone marrow-derived DCs were generated from 4 to 6 weeks
old C57BL/6 male mice. DCs were cultured as described
previously [20] with some modification. DCs were cultured in
RPMI-1640 medium containing 10% FBS (Atlanta Biosciences),
with 10 ng/mL each of recombinant granulocyte–macrophage
colony-stimulating factor (GM-CSF) and Interleukin-4 (IL-4) from
PeproTech Inc. (Rock Hill, NJ). On day 3 of culture, fresh
medium was added to the DC cultures. On day 6 of culture, DCs
were exposed for 4 hr to the CD40-retargeted Ad5-huPSMA at
MOI 100. Subsequently, the DCs were matured by incubating
with 100 ng/mL lipopolysaccharide (LPS, Sigma; St Louis, MO)
overnight. The matured DCs were washed twice with PBS and
administered by intraperitoneal (i.p.) injection into C57BL/6
mice.
Immune Response after Vaccination using DCs
Stimulated ex vivo with Ad5-huPSMA
The mice were vaccinated with Ad-infected DCs (16106 cells/
mouse) suspended in sterile PBS in a total volume of 50 mL by i.p.
injection on day 0 and 14. On day 24, the mice were euthanized
and spleens were harvested. Single cell suspensions were prepared
by mincing the spleens in serum-free RPMI medium with scissors
and gentle repeated pipetting, followed by passing the suspensions
through 100 mM nylon mesh. The red blood cells were lysed with
lysis buffer, and the purified T-cells were washed twice in serum-
free medium, counted, and seeded at a density of 16106 cells per
well of 24-well plates in 500 mL of serum-free medium.
Immune Response after Direct Vaccination in vivo with
Ad5-huPSMA
C57BL/6 mice were immunized by direct i.p. injections with
Ad5-huPSMA. Each mouse was injected with 16109 ifu of Ad5-
huPSMA alone or 16109 ifu of Ad5-huPSMA complexed with
1200 ng of CFm40L on day 0. A second dose was administered 14
days later. At 24 days after the initial immunization, the mice were
euthanized and the spleens were collected and T-cells cultured as
described above.
Generating CTLs and Performing Cytotoxicity Tests
Cultured T-cells from the mouse spleens were re-stimulated for
6 days by the addition of irradiated HEK-293 cells infected with
Ad5-huPSMA to over express the PSMA antigen. Following re-
stimulation, T-cells were harvested and separated from the dead
cells. The cytotoxicity was determined in a standard 4 h
chromium release assay using the stimulated T-cells as effector
cells (E) and RM-1 cell lines as specific targets (T) at the indicated
E:T ratios. The RM-1 cell lines (RM-1-PSMA clone 1, RM-1-
PSMA clone 3, and RM-1-GFP clone 2) were used directly as
target cells or were previously incubated for 24 h with Ad5-IFNc
(MOI 100). The cells were labeled with 100 mCi of Na251CrO4 for
1.5 h at 37uC. Subsequently, 16103 labeled target cells were co-
cultured with different numbers of effector cells in a 96-well (v-
bottom plates) for 4 h at 37uC. At the end of the culturing, 100 mL
of supernatants were collected and radioactivity was measured on
a gamma-counter. Maximum and spontaneous release of 51Cr was
obtained from the supernatants of the target cells in 1% Nonidet
P-40 and in medium alone respectively. All experiments were
performed with quadruplicate wells. The 51Cr-release was
measured by a gamma counter (LKB Instruments, Gaithersburg,
MD), and the percent specific lysis was calculated by the following
formula: % specific lysis = [(experimental c.p.m. - spontaneous c.p.m.)/
(maximal c.p.m. - spontaneous c.p.m.)]6100.
Flow Cytometry Analysis of NKG2D Ligand Expression
RM-1-PSMA clone 3 cells and YAC-1 cells were plated at
100,000 cells/well into 24-well tissue culture dishes. The cells were
allowed to attach by overnight incubation at 37uC. On the
following day, the cells were incubated in the absence or presence
of Ad5-IFNc at 100:1 MOI at 37uC in serum-free media. At 2 h
post-infection, the virus-containing media was replaced with
complete growth medium containing 10% FBS. After 48 h, the
untreated or Ad5-IFNc treated cells were harvested and washed
twice with PBS. The cells were incubated for 1 h at 4uC with
phycoerythrin (PE) labeled rat IgG2A isotype control antibody
(R&D Systems, Minneapolis, MN) or with the following anti-
bodies: (a) a PE labeled rat anti-mouse H60 monoclonal antibody
(R&D Systems), (b) a PE labeled rat anti-mouse Rae-1 (pan-
specific) monoclonal antibody (R&D Systems), or (c) a PE labeled
rat anti-mouse MULT-1 monoclonal antibody (R&D Systems).
Following the antibody incubation, the cells were washed twice
with PBS, resuspended in 0.4 ml PBS, and analyzed by flow
cytometry using a FACS Calibur instrument (Becton Dickinson,
San Jose, CA).
Figure 5. Analysis of TAP expression in RM-1 cell lines induced
by Ad5-IFNc. Protein extracts (20 mg) were prepared from each cell line
and diluted with RIPA sample buffer. The extracts were separated by
SDS-PAGE, electroblotted onto nitrocellulose and probed with (A) an
anti-mouse TAP1 antibody or (B) an anti-mouse TAP2 antibody,
followed by treatment with a corresponding anti-mouse IgG HRP
conjugates. Shown are representative blots after visualization by
autoradiography. A loading control was used by co-treatment of the
membranes with an anti-mouse GAPDH antibody.
doi:10.1371/journal.pone.0046981.g005
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Cell Viability Assay
RM-1 and RM-1-PSMA clone 3 cells were seeded onto 96-well
plates (2,000 cells/well) with DMEM containing 10% fetal bovine
serum. Following an overnight incubation, the cells were infected
with Ad5-IFNc at increasing MOI (0, 0.1, 1, 10, 100, 1000 ifu/cell)
in serum-free medium at 37uC. The Ad5-IFNc containing medium
was aspirated after 2 h and replaced with complete growth
medium. A cell viability assay was performed at days 1, 2, 3, and 4
post-infection using the CellTiter-Blue reagent (Promega, Madi-
son, WI) by following manufacturer’s instructions. Briefly, at each
time point, 20 mL of CellTiter-Blue reagent was added to the wells
and mixed for 10 sec on a shaker. The cells were then incubated
for another 22 h at 37uC. Afterwards, the fluorescence signal in
each well was analyzed using a Fluoroskan Ascent microplate
fluorometer (Thermo Fisher Scientific, Waltham MA) with an
excitation setting at 530 nm and an emission setting at 620 nm.
Splenic Effector Cell Isolation
Control (untreated) male C57/BL6 mice were euthanized by
CO2 asphyxiation. Spleens were harvested and homogenized
manually between the ends of frosted glass microscope slides and
passed through a 70-m mesh. Dispersed splenic cells were
centrifuged at 1,000 rpm in a tabletop centrifuge for 5 min and
resuspended in red blood cell (RBC) lysis buffer (138 mM NH4Cl,
1 mM KHCO3, and 0.1 mM EDTA) for 5 min. The remaining
splenocytes were washed three times in ice-cold PBS. Cell
suspensions were counted and adjusted to 16107 cells/mL.
Chromium Release Assay
To measure sensitivity of RM-1 cells to mouse NK cell lysis,
a chromium release assay was performed. Initially, RM-1 cells or
RM-1-PSMA clone 3 cells were plated into 100 mm tissue culture
dishes. The cells were allowed to attach by overnight incubation at
37uC. On the following day, the cells were incubated in the
absence or presence of Ad5-IFNc at 100:1 MOI at 37uC in serum-
free media. At 2 h post-infection, the virus-containing media was
replaced with complete growth medium containing 10% FBS.
After 48 h, the untreated or Ad5-IFNc treated cells were harvested
by trypsinization and labeled with 51Cr. The target cells were
counted and resuspended at a concentration of 16107 cells/mL of
medium. To each cell suspension, 125 mCi of 51Cr (ICN
Pharmaceuticals, Costa Mesa, CA) was added as an aqueous
solution of sodium chromate and incubated for 90 minutes at
37uC with swirling every 15 minutes. The labeled target cells were
washed once in PBS and three times in complete medium. To
initiate the chromium release assay, the isolated splenocyte effector
cells were added to the wells of U-bottomed 96-well plates (100,
50, 25, and 12.5 mL for each cell target) in replicates of four. All
wells were brought to a final volume of 100 mL with complete
medium. Two sets of controls were employed instead of effector
cells: one set contained only 100 mL of complete medium to
account for spontaneous 51Cr release and one set contained
100 mL of 2N HCl to account for maximum 51Cr release. The
labeled target cells were adjusted to 16105 cells/mL, and 100 mL
was quickly added to each of the wells on the plate. The plates
were then incubated at 37uC for 4 hours. Following incubation,
the plates were centrifuged at 1,200 rpm for 5 minutes to pellet the
cells. A portion (100 mL) of the resulting supernatant was removed
to glass tubes for analysis using a gamma counter, and the percent
specific lysis was calculated by the following formula: % specific
lysis = [(experimental c.p.m. - spontaneous c.p.m.)/(maximal c.p.m. -
spontaneous c.p.m.)]6100.
Tumor Challenge Experiment
Groups of fifteen C57BL/6 mice were immunized by direct i.p.
injection with Ad5-huPSMA. Each mouse was injected with 16109
ifu of Ad5-huPSMA alone or 16109 ifu of Ad5-huPSMA complexed
with 1,200 ng of CFm40L on day 0. A second dose was
administered 14 days later. The parental RM-1 cell line or the
RM-1-PSMA clone 1 cell line were harvested from cell culture
flasks using 1% trypsin and washed with PBS. Subsequently, the
cells were injected into the C57BL/6 mice immunized as
described above. Each mouse received 46105 cells injected at
day 24 after initiation of the immunization regimen. Subsequently,
tumor volume was measured with a digital caliper (VWR
INTERNATIONAL; WAYNE, PA) every four days. At each
tumor measurement, the greatest longitudinal diameters (length)
and the greatest transverse diameters (width) were measured, and
the tumor volumes were estimated using the formula: tumor
volume =K6 (length6width2).
Statistical Analysis
Data are presented as mean 6 standard error (SEM) of the data
points. Statistical analysis was performed using Student’s t-test,
using GraphPad Prism 5.0 software (GraphPad Software, Inc.; La
Jolla, CA). Data were considered statistically significant when
P,0.05.
Results
RM-1 Mouse Prostate Cancer Cell Lines Expressing
Human PSMA
The full-length human PSMA cDNA sequence was cloned into
mammalian expression plasmid vector pEF1/V5-His downstream
of the enhancer/promoter elements from the human elongation
factor 1a subunit (hEF-1a) for high-level expression in mammalian
cells. As a negative control, the green fluorescent protein (GFP)
cDNA was also cloned into the pEF1/V5-His expression vector.
The mouse prostate cancer cell line RM-1 was transfected with the
expression vectors, and individual clones were isolated by G418
selection followed by limiting dilution. Three individual clones
were isolated: RM-1-PSMA clone 1 and RM-1-PSMA clone 3
express the human PSMA cDNA and RM-1-GFP clone 2
expresses the GFP cDNA. In order to characterize the growth
properties of the clones in culture, the cell numbers were measured
over 7 days of culturing. As shown in Fig. 1, the results
demonstrate that under normal growth conditions, all three
RM-1 cell lines grow in a similar fashion as the parental RM-1 cell
line.
Western Blot Analysis of PSMA Expression
To determine the level of PSMA expression in the selected RM-
1 clones, Western blot analysis was performed using rabbit
polyclonal antibodies prepared from peptides corresponding to the
C-terminal sequence or the N-terminal sequence of the human
PSMA. Lysates from the two RM-1-PSMA clones were loaded on
Figure 6. Effect of cell viability on cell lines after infection in vitro with Ad5-IFNc. Shown is a representative curve of the cell viability in (A)
RM-1 cells or (B) RM-1-PSMA clone 3 cells infected in culture with increasing concentrations of Ad5-IFNc compared with uninfected cells. Effect of cell
viability was determined at day 1 (N), day 2 (.), day 3 (X), and day 4 (&) after initiation of infection with Ad5-IFNc. Each data point represents the
mean 6 standard error of three independent experiments.
doi:10.1371/journal.pone.0046981.g006
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Figure 7. CTL assays of T-cells from mice after ex vivo infection of DCs with the CD40-targeted Ad5 vectors expressing PSMA or
luciferase followed by intraperitoneal administration. Mice were immunized as described in Material and Methods with dendritic cells
infected with the CD40-targeted Ad5-luc1 or with the CD40-targeted Ad5-huPSMA. At day 24 after initiation of the experiment, the animals were
euthanized, and CTL activity was measured in cells harvested from the spleens. Target cells used were RM-1 parental (N), RM-1-PSMA clone 1 cells
(.), RM-1-PSMA clone 3 cells (X), and RM-1-GFP clone 2 cells (&). Target cells were either untreated (A and C) or pre-treated by infection with Ad5-
IFNc (B and D). Each data point represents the mean 6 standard error of four replicate wells.
doi:10.1371/journal.pone.0046981.g007
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gel and compared to the lysates from control (parental) RM-1 cells
and RM-1-GFP cells. As shown in Fig. 2A, predicted bands of
approximately 100 kDa was visualized in the RM-1-PSMA clone
1 and clone 3 but not in the parental RM-1 cells or in RM-1-GFP
cells. Levels of PSMA expression were similar in both RM-1-
PSMA clones. In addition, PSMA detection with antibodies
targeting either N-terminal or C-terminal sequences revealed
identical staining pattern with no sign of abnormal expression or
protein degradation (Fig. 2B).
Constructing a CD40-targeted Ad Vector to Deliver PSMA
to DCs
Previous studies have demonstrated that targeting to mouse
CD40 enhanced Ad-mediated gene transfer to mouse DC, which
was accompanied by phenotypic changes characteristic of DC
maturation [14]. This targeting approach was achieved using an
adapter molecule that bridges the fiber of the Ad5 to CD40 on
mouse DC. We utilized an Ad vector, which incorporated a human
PSMA expression cassette within the E1A region under the control
of the CMV promoter (Ad5-huPSMA). We then tested this vector
on the ability to infect mouse DCs, which has been shown
previously to poorly express the Coxsackie and adenovirus
receptor but to be CD40 positive [21]. The optimal CFm40L
concentration (lowest amount of CFm40L achieving maximal DC
infection) was determined to be 120 ng CFm40L per 16108 ifu
(infectious units) of virus at a multiplicity of infection (MOI) at 100
ifu Ad5-huPSMA per cell (data not shown). Western blot analyses
confirmed PSMA expression (Fig. 3A) in cells infected with Ad5-
huPSMA which peaked at 24 h post-infection and was maintained
for up to 48 h (Fig. 3B). These experiments demonstrate efficient
infection of mouse DCs with Ad5-huPSMA and efficient expression
of the PSMA antigen.
Cell Surface Expression of MHC Class IA Molecules in
Response to IFNc
RM-1 cells have been previously shown to express low levels of
MHC class I (Db and Kb) [22], which can be up regulated by
treatment with recombinant IFNc [23]. Cell surface expression of
MHC class I molecules on RM-1 cells after infection with Ad5-
IFNc was determined by flow cytometry. Low basal cell surface
expression of MHC class I antigens was observed for the parental
RM-1 cell line as well as the RM-1-PSMA clones 1 and 3 and the
RM-1-GFP clone 2 cell lines in the absence of Ad5-IFNc
treatment. Treatment with 100 ifu Ad5-IFNc per cell for 24 h
dramatically increased MHC class I cell surface expression on
each of the RM-1 cell lines compared with untreated control cells.
The results of this experiment show that the RM-1 and all of the
clonal cell lines have low cell surface expression of MHC class I,
while treatment of the cells with Ad5-IFNc showed marked up
regulation of MHC class I expression (Figs. 4A - D).
Western Blot Analysis of TAP1 and TAP2 Protein
Expression in RM-1 Cell Lines
Antigenic peptides are generated in the proteasome of target
cells, and then translocated across the membrane of the
endoplasmic reticulum by the transporter associated with antigen
processing (TAP). TAP is a trimeric complex consisting of TAP1,
TAP2 and tapasin [24]. To characterize the antigen presentation
pathway in RM-1 cells, expression of TAP1 and TAP2 proteins
was analyzed by Western blotting. As shown in Fig. 5A and Fig. 5C,
TAP1 protein levels were undetectable and TAP2 protein levels
were barely detectable in any of the RM-1 cell lines. However,
treatment with Ad5-IFNc for 24 h dramatically increased both
TAP1 and TAP2 protein expression in each of the RM-1 cell lines
(Fig. 5B and Fig. 5D) compared with the untreated cells. These
results demonstrate that Ad5-IFNc induces expression of the MHC
class I antigen presentation pathway in RM-1 cells.
Effect of Ad5-IFNc on Cellular Viability
IFNc can activate and suppress a number of different target
genes, leading to decreased cellular viability by inducing cell cycle
arrest and apoptosis. To determine any effect IFNc had on cellular
viability, RM-1 and RM-1-PSMA clone 3 cells were infected with
Ad5-IFNc ranging from 0.1 to 1,000 ifu/cell and assayed at days 1,
2, 3, and 4 after infection. As shown in Fig. 6, cell viability was
unchanged in cells infected at any concentration of Ad5-IFNc
compared with untreated cells. No decrease was observed up to 4
days after infection, either in RM-1 cells (Fig. 6A) or in RM-1-
PSMA clone 3 cells (Fig. 6B); these results indicate that there is no
direct effect of IFNc on cellular viability in vito.
CTL Assay of Mouse Splenocytes after in vivo
Administration of DCs Treated ex vivo with the CD40-
targeted Ad Vectors
To study the effect of CD40-targeted Ad infection on DC-
mediated CTL activation, we used two CD40-targeted Ad vectors:
Ad5-luc1 or Ad5-huPSMA. In the experiment shown in Fig. 7,
C57BL/6 mice were immunized with 36106 DCs infected with
either the CD40-targeted Ad5-luc1 or with the CD40-targeted Ad5-
huPSMA. This immunization was repeated at 14 days; at 24 days
from initiation of the immunization regimen, the mice were
sacrificed and the spleens were removed and T-cells cultured. T-
cells from the mice were re-stimulated for 6 days with c-irradiated
293 cells infected with Ad5-huPSMA. Following re-stimulation,
a 51Cr release CTL assay was performed with the stimulated CTL
as effector cells (E) and RM-1 cells targets (T) at the indicated E:T
ratios. Cytotoxicity was measured using parental RM-1 target
cells, the RM-1 clonal cell lines 1 and 3 expressing PSMA, or the
RM-1 clonal cell lines 2 expressing GFP. IFNc induces the
expression of several components of the antigen-processing
machinery, leading to enhanced presentation of peptides in the
context of HLA class I molecules on the cell surface [25].
Therefore, we decided to enhance CTL lysis of target cells by
infecting them with an Ad vector expressing the murine interferon-
gamma (Ad5-IFNc).
T-cells from mice in the vaccination group receiving DCs
infected with the CD40-targeted Ad5-luc1 did not acquire CTL
activity (Fig. 7A). Likewise, there was no specific lysis using target
cells treated with Ad5-IFNc (Fig. 7B).However, as shown in Fig. 7C,
T-cells from mice in the vaccination group receiving DCs infected
with the CD40-targeted Ad5-huPSMA exhibited weak specific lysis
against RM-1-PSMA clone 3 cells (with a significance of P,0.05
Figure 8. CTL assays of T-cells from mice after direct intraperitoneal administration of CD40-targeted vectors expressing PSMA or
luciferase. Mice were immunized as described in Material and Methods with the CD40-targeted Ad5-luc1 or with the CD40-targeted Ad5-huPSMA. At
day 24 after initiation of the experiment, the animals were euthanized, and CTL activity was measured in cells harvested from the spleens. As a control,
CTL activity was measured in cells harvested from spleens of naı¨ve (untreated) mice. Target cells used were RM-1 parental (N), RM-1-PSMA clone 1
cells (.), RM-1-PSMA clone 3 cells (X), and RM-1-GFP clone 2 cells (&). Target cells were either untreated (A, C, and E) or pre-treated by infection with
Ad5-IFNc (B, D, and F). Each data point represents the mean 6 standard error of four replicate wells.
doi:10.1371/journal.pone.0046981.g008
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at E:T ratios of 100:1, 50:1 and 25:1) and RM-1-PSMA clone 1
cells (with a significance of P,0.05 at E:T ratios of 100:1 and
50:1), compared to control RM-1 cells or to RM-1-GFP clone 2
cells. Importantly, as shown in Fig. 7D, CTL lytic activity was
significantly enhanced in RM-1-PSMA clone 1 and RM-1-PSMA
clone 3 cells, which were pre-treated for 24 h with Ad5-IFNc.
However, neither RM-1 cells nor RM-1-GFP clone 2 cells, which
were also pre-treated with Ad5-IFNc showed any specific lysis. The
differences between control RM-1 cells and either of the two cell
Figure 9. Assessment of sensitivity to NK cell-mediated cytotoxicity. (A) Cytotoxic activity of NK effector cells on YAC-1 and RM-1 target cells
was determined by a 51Cr-release assay at indicated E:T ratios. Target cells used were YAC-1 (N), RM-1 parental (.), RM-1 parental cells pre-treated by
infection with Ad5-IFNc (&), RM-1-PSMA clone 3 cells (X), or RM-1-PSMA clone 3 cells pre-treated by infection with Ad5-IFNc (m). Each data point
represents the mean 6 standard error of four replicate wells. (B) Flow cytometry analysis of YAC-1 and RM-1 cells stained with PE labeled anti-H60,
anti-MULT-1, or anti-Rae-1 antibodies or with an isotype-matched control antibody. Numbers below the histograms correspond to mean fluorescence
intensity of each peak.
doi:10.1371/journal.pone.0046981.g009
Figure 10. Assessment of tumor growth after vaccine treatment. Antitumor effect of a CD40-targeted Ad5-huPSMA vaccine was determined
using the RM-1-PSMA mouse model. Mice were immunized as described in Material and Methods with the CD40-targeted Ad5-luc1 or CD40-targeted
Ad5-huPSMA. At day 24 after initiation of the experiment, each mouse received 46106 RM-1 parental cells or 46106 RM-1-PSMA clone 1 cells injected
subcutaneously. Three days later, the treatment groups were injected at the site of tumor cell injection with 16108 ifu of Ad5-IFNc or with normal
saline. Beginning at the time of tumor cell challenge (day 0), the tumors were measured and volumes calculated by the formula: tumor volume=K6
(length6width2) where length is the longest distance of the tumor. Each data point represents the mean volume of 15 tumors 6 standard error.
doi:10.1371/journal.pone.0046981.g010
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lines expressing PSMA (RM-1-PSMA clone 1 or RM-1-PSMA
clone 3) were statistically significant at all E:T ratios (P,0.01).
CTL Assay after Vaccination with Ad5-huPSMA
The following experiment tested the functionality of the CD40-
targeted Ad5-huPSMA to deliver an antigen to DCs in situ. In this
experiment, DC-mediated CTL activation was assessed after
direct intraperitoneal (i.p.) injection of the CD40-targeted Ad5-
huPSMA. As shown in the vaccination schema in Fig. 8, C57BL6
mice were immunized i.p. with 16108 ifu of either the CD40-
targeted Ad5-luc1 or the CD40-targeted Ad5-huPSMA. This
immunization was repeated at 14 days with 16108 ifu of the
CD40-targeted Ad. At 24 days from initiation of the immunization
regimen, the mice were sacrificed and the spleens were removed
and T-cells cultured. T-cells from the mice were re-stimulated as
described above, followed by a classic 51Cr release CTL assay.
Cytotoxicity was measured by 51Cr release from RM-1 target cells
or RM-1 clonal cell lines expressing either PSMA or GFP.
As shown in Fig. 8A, T-cells from naive mice exhibited no
specific lysis against any of the RM-1 cell lines. In, addition, no
specific lysis was detected when the target cells were pre-treated
with Ad5-IFNc (Fig. 8B). Similarly, when mice were vaccinated in
situ with the CD40-targeted Ad5-luc1, no specific lysis against any
of the RM-1 cell lines was observed, regardless of their pre-
treatment with Ad5-IFNc (Fig. 8C and Fig. 8D). When mice were
vaccinated with the CD40-targeted Ad5-huPSMA, RM-1-PSMA
clone 3 did show weak CTL lysis. However, no significant 51Cr
release was observed neither with parental RM-1 cells, nor RM-1-
GFP clone 2 or RM-1-PSMA clone 1 (Fig. 8E). Significantly, as
shown in Fig. 8F, specific lysis was dramatically enhanced in RM-
1-PSMA clone 1 and RM-1-PSMA clone 3, when those cells were
pre-treated with Ad5-IFNc. Importantly, neither RM-1 parental
cells nor RM-1-GFP clone 2, which were also pre-treated with
Ad5-IFNc showed any specific lysis.
Assay of RM-1 Cells to Natural Killer (NK) Cell-mediated
Cytotoxicity
NK cells play a major role in host defense against developing
tumors and virally infected cells; thus, we investigated the
sensitivity of RM-1 cells to NK cell-mediated cytotoxicity. To
determine the sensitivity of the RM-1 and RM-1-PSMA clone 3
cell lines as targets for NK cell lysis, a chromium release assay was
performed using mouse splenocytes. Although NK cells were not
purified, they represent the only cell population capable of lysing
the effector cells in this assay. As a control, an NK-sensitive cell
line (YAC-1 mouse lymphoma cells) was also assayed. As shown in
Fig. 9A, both the RM-1 and RM-1-PSMA clone 3 cell lines were
insensitive to lysis by NK cells compared with YAC-1 cells. In the
4-hour incubation, very little or no cytolytic activity was detected,
even in RM-1 and RM-1-PSMA clone 3 cells pretreated with Ad5-
IFNc. These results suggest that RM-1 cells are resistant to NK-
mediated killing. To gain insight into the mechanism responsible
for NK resistance, expression of NKG2D ligands on RM-1 clone 3
cells was investigated, since the expression of NKG2D ligands has
been previously demonstrated to play important role in NK-
mediated killing. As shown in Fig. 9B, the mean fluorescence
intensities of immunostaining the murine NKG2D ligands H60,
Rae-1, and MULT-1 were lower in RM-1 cells compared to YAC-
1 cells (an NK-sensitive cell line) used as positive control. Similar
low expression of NKG2D ligands was observed in RM-1 cells
pretreated with Ad5-IFNc (data not shown). These results suggest
that low expression of NKG2D ligands in RM-1 cells may be
involved in the resistance to NK-mediated killing we observed.
Tumor Response after Vaccination in vivo
Finally, we asked if CD40-targeted Ad5-huPSMA vaccine could
induce an immune response to control tumor growth. In this
experiment, C57BL/6 mice were immunized by intraperitoneal
injection of 16108 ifu of untargeted Ad5-huPSMA or CD40-
targeted Ad5-huPSMA. The animals received a boost immunization
at 10 days after the initial immunization. At the 14th day after the
second immunization, the mice were challenged subcutaneously
with 46105 RM-1 parental cells or RM-1-PSMA clone 1 cells.
Three days later, the treatment groups were injected at the site of
tumor cell injection with 16108 ifu of Ad5-IFNc or with normal
saline. As shown in Fig. 10, immunization with CD40-targeted
Ad5-huPSMA alone or with non-targeted Ad5-huPSMA + Ad5-IFNc
similarly diminish tumor growth in animals challenged with RM-
1-PSMA cells. This tumor growth was significantly delayed
compared with the animals immunized with the CD40-targeted
Ad5-huPSMA but challenged with parental RM-1 cells (that do not
express the human PSMA antigen). Importantly, mice immunized
with the CD40-targeted Ad5-huPSMA and Ad5-IFNc demonstrated
the greatest inhibition of tumor growth when challenged with RM-
1-PSMA cells compared with the other groups.
Discussion
In this study, we evaluated a prostate cancer vaccine based on
adenoviral vector delivering PSMA antigen targeted by means of
a bispecific adapter approach to CD40 expressing DCs. PSMA is
a prostate tumor antigen that is widely expressed on the surface of
prostate cancer cells. Generation of an appropriate immune
response against tumor-specific antigens leading to eradication of
tumors is of prime importance. Thus, our main goal in the study
was to determine a proof-of-principle in using the Ad vaccine to
directly stimulate DCs in vivo to target PSMA expressing prostate
cancer cells. The major hurdle in targeting dendritic cells by
means of adenoviral vectors is the lack of the native Coxsackie and
Adenovirus receptor on the cell surface. We demonstrated
expression of PSMA upon infection of DCs using a CD40-targeted
Ad5-huPSMA vector, while using an untargeted vector resulted in
undetectable PSMA expression. A major advantage using the
adapter-based CD40-targeting approach is flexibility to use
different sets of Ad vectors expressing unique tumor associated
antigens. Our results also have relevance that would encourage the
use of Ad vectors in immunotherapies targeting additional cancers
in addition to prostate cancer.
MHC molecules play a critical role in the immune response
against target antigens. Several studies have reported that MHC
class I allele is frequently down regulated in as many as 85% of
prostate tumors. The loss of MHC expression may be one of the
potential mechanisms by which cancer cells evade host immuno-
surveillance. We show in this study that the parental RM-1 cells
and their derivative clonal cell lines do not express detectable
levels of MHC class I on their cell surface. However, pretreatment
of RM-1 cells with Ad5-IFNc led to significant up regulation of
MHC class I as evident by flow cytometry analysis. Furthermore,
since TAP1 and TAP2 form important components of the antigen
presentation pathway, we studied their expression in RM-1 cells
by Western blot analysis. These results indicate that RM-1 cells
express low levels of TAP1 and TAP2, which may explain their
propensity to form tumors and evade the immune response.
Importantly, infection with Ad5-IFNc induces TAP1 and TAP2
expression in the RM-1 cell lines. Thus, these results suggest that
effective vaccine therapy in the context of the RM-1 model
requires combination vaccine therapy using an immunomodula-
tory molecule to stimulate antigen presentation in target cells.
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DCs play a functional role in eliciting cellular immune response
against tumor specific antigens. We assessed the ability of CD40-
targeted Ad infection on DC-mediated CTL activation in an in
vitro 51Cr release CTL assay. We found efficient killing of the target
RM-1 clone 1 and clone 3 cells expressing PSMA antigen by the T
cells obtained from mice injected with DCs infected with Ad5-
huPSMA. This lytic activity was further enhanced by infection of
cells with an Ad vector expressing murine IFNc. However, the
CTL killing activity was absent in the group of animals receiving
DCs infected with untargeted vector Ad5-luc1. The efficacy of
CD40-targeted Ad5-huPSMA to deliver the antigen to DCs and
induce CTL response was further tested using an in vivo CTL
assay. Our data demonstrate weak killing of target RM-1-PSMA
clone 3 by the T cells isolated from the mice immunized with Ad5-
huPSMA as opposed to the animals treated with Ad5-luc1. This
CTL lytic activity was dramatically enhanced in the PSMA
expressing RM-1 clonal cell lines upon the treatment with Ad5-
IFNc, emphasizing on the significance of the combination vaccine
therapy using immunomodulatory molecules to stimulate the CTL
activity against tumor antigens.
In our experiments, we observed the most significant delay in
the growth of RM-1-PSMA tumors in mice immunized with the
CD40-targeted Ad5-huPSMA when the mice were also adminis-
tered Ad5-IFNc. Mice challenged with RM-1 cells that do not
express human PSMA did not show inhibition of tumor growth.
This suggests that the DC-based vaccine may confer resistance to
the prostate tumor growth in vivo in an antigen specific manner.
However, mice immunized with CD40-targeted Ad5-huPSMA
without Ad5-IFNc, and challenged with RM-1-PSMA cells offered
intermediate protection against tumors. Likewise, mice immunized
with untargeted Ad5-huPSMA but including Ad5-IFNc, and
challenged with RM-1-PSMA cells offered similar intermediate
protection against tumors. It is possible that weak CTL activity
was sufficient to offer some protection in these contexts. It is also
possible that IFNc itself offered some indirect anti-cancer pro-
tection. IFNc has been shown to be capable of bestowing increased
sensitivity to Fas-mediated cell death in prostate cancer cells [26].
Although delayed, growth of RM-1-PSMA tumors ultimately
resumed in mice immunized with the CD40-targeted Ad5-huPSMA
co-treated with Ad5-IFNc. Nonetheless, these mice demonstrated
a prolonged survival advantage. In conclusion, our study may aid
the development of dendritic cell based cancer gene therapy
approaches for the therapeutic intervention of prostate carcinoma.
Future studies are warranted to explore the mechanisms involved
in mediating protection against the PSMA expressing tumors as
well as to maximize the therapeutic effect.
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